Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.39 USD
-0.03 (-2.11%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
Coherus BioSciences, Inc. [CHRS]
Reports for Purchase
Showing records 41 - 60 ( 70 total )
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Coherus Provides Overview of Toripalimab Development Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Good News Ahead of ASCO: Toripalimab Chemo Combo Meets PFS Endpoint in First Line Recurrent NPC Phase 3; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Udenyca Buffeted by Near-term Headwinds, Toripalimab Begins to Move Center Stage
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Toripalimab Hits Endpoint in Esophageal Cancer Phase 3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Coherus Takes Big Step in Entering the PD-1 Space With Submission of Rolling US BLA in NPC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Effects of COVID Felt in 4Q20 and Expected to Carry Into 2021; Reiterate Buy, Lower PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
An Innovator in Biosimilars Turns to Innovation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Lucentis Biosimilar Shows Similarity Beyond the Topline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Udenyca Misses High Expectations; Reiterate Buy; But Downtick Price Target to $32 from $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Our Coverage at the 2020 H.C. Wainwright Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Udenyca Flashes More Strength; Reiterate Buy and Raise PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Udenyca Continues to Show Strength, Balance Sheet Affords Opportunism; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Strong 1Q Despite Covid-19 Impact, Effects Should Prove Transient; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Another Quarter to Validate Its Business Model; Target to $30, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
An Unfortunate Move Leads to a Modest Delay for Lucentis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Coherus BioSciences, Inc.
Industry: Medical - Biomedical and Genetics
Updating Model for Biosimilar Lucentis Acceleration; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D